• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PhenomeX to Report Second Quarter 2023 Financial Results on August 14, 2023

    8/9/23 4:25:00 PM ET
    $CELL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CELL alert in real time by email

    EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023.

    CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)">

    About PhenomeX Inc.

    PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease.  Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding PhenomeX or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. PhenomeX undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/phenomex-to-report-second-quarter-2023-financial-results-on-august-14-2023-301897282.html

    SOURCE PhenomeX

    Get the next $CELL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CELL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CELL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform

      EMERYVILLE, Calif., Sept. 27, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, announced the Opto® Memory B Discovery Human workflow, further expanding diversity of antibodies customers can discover on the Beacon® optofluidic platform. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists

      9/27/23 8:51:00 AM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care
    • PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

      Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression.

      9/21/23 8:35:00 AM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care
    • PhenomeX to Participate in Upcoming Cell Biology Conferences

      New Beacon platform data to be presented by Genovac at Discovery on Target 2023 Poster and podium presentation featuring the Beacon platform to be presented at Annual Festival of Biologics Basel Conference & Exhibition EMERYVILLE, Calif., Sept. 20, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming cell biology conferences. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advan

      9/20/23 8:48:00 AM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care

    $CELL
    Financials

    Live finance-specific insights

    See more
    • PhenomeX Reports Second Quarter 2023 Financial Results and Provides Business Update

      Strategic Alternatives Process Continuing; Board Focused on Maximizing Stockholder Value EMERYVILLE, Calif., Aug. 14, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the second quarter ended June 30, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scien

      8/14/23 4:05:00 PM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care
    • PhenomeX to Report Second Quarter 2023 Financial Results on August 14, 2023

      EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists to leverage the fu

      8/9/23 4:25:00 PM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care
    • PhenomeX Reports First Quarter 2023 Financial Results

      Company provides full year 2023 financial guidance EMERYVILLE, Calif., May 11, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the first quarter ended March 31, 2023. Following the completion of Berkeley Lights' acquisition of IsoPlexis on March 21, 2023, the newly combined company was rebranded as PhenomeX and is positioned to be the leading provider of life sciences solutions that have the greatest impact in advancing the era of the phenome as the next revolution in biology and medicine unfolds. Its brand reflects the Company's mission to empower scientists to leverage the full potential of each cell and drive the next

      5/11/23 4:02:00 PM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care

    $CELL
    Leadership Updates

    Live Leadership Updates

    See more
    • PhenomeX Appoints Peter Silvester to PhenomeX Board of Directors

      EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- PhenomeX (NASDAQ:CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately. Mr. Silvester most recently served as senior vice president and president of Life Sciences Solutions for Thermo Fisher Scientific and brings more than 25 years of experience in the life sciences tools industry as an executive and board member. "Peter's wealth of knowledge within the life sciences industry and experience in global business and commercial oper

      4/10/23 8:35:00 AM ET
      $CELL
      Medicinal Chemicals and Botanical Products
      Health Care